First Enron and Andersen. Then Merrill Lynch. Now ImClone.

With news this month that the New York biotech company's former CEO had been arrested on charges of insider trading, analysts and fund marketers said the scandal was yet another reason for investors to worry at a time when the investment industry is trying frantically to keep the trust of its patrons.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.